VIP modulation of immune cell functions
- PMID: 8790783
- DOI: 10.1016/s0960-5428(96)00002-2
VIP modulation of immune cell functions
Abstract
Neuropeptides have recently been shown to modulate the immune response. Vasoactive intestinal peptide (VIP) released from nerve endings and from immune cells modulates the mobility and adherence of lymphocytes and macrophages, phagocytic cell functions (phagocytosis and free radical production), the lymphocyte proliferative response, lymphokine and immunoglobulin production and the natural killer cell activity, with opposite effects in vitro on these immune cell functions. The VIP receptor heterogeneity and the different action mechanisms of VIP-mediated immunoregulation could explain, at least in part, the different VIP effects observed on lymphoid and phagocytic cells. The evidence supports the theory that VIP acts not as an inhibitor, but as a modulator of immune functions, as previously thought, and that this neuropeptide may play a relevant role in vivo.
Similar articles
-
Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs.Adv Neuroimmunol. 1996;6(1):61-74. doi: 10.1016/s0960-5428(96)00007-1. Adv Neuroimmunol. 1996. PMID: 8790782 Review.
-
Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system.Adv Neuroimmunol. 1996;6(1):29-36. doi: 10.1016/s0960-5428(96)00001-0. Adv Neuroimmunol. 1996. PMID: 8790779 Review.
-
Biochemical characteristics of receptors for vasoactive intestinal polypeptide in nervous, endocrine, and immune systems.Fed Proc. 1987 Jan;46(1):192-5. Fed Proc. 1987. PMID: 3026856 Review.
-
Immunology of VIP: a review and therapeutical perspectives.Curr Pharm Des. 2001 Jan;7(2):89-111. doi: 10.2174/1381612013398374. Curr Pharm Des. 2001. PMID: 11172702 Review.
-
VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.J Immunol. 1999 Oct 15;163(8):4213-23. J Immunol. 1999. PMID: 10510358
Cited by
-
From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.Cells. 2023 Nov 17;12(22):2649. doi: 10.3390/cells12222649. Cells. 2023. PMID: 37998384 Free PMC article. Review.
-
Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.Mol Pharm. 2013 Feb 4;10(2):728-38. doi: 10.1021/mp300539f. Epub 2013 Jan 23. Mol Pharm. 2013. PMID: 23211088 Free PMC article.
-
Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.Peptides. 2007 Sep;28(9):1833-46. doi: 10.1016/j.peptides.2007.04.008. Epub 2007 Apr 20. Peptides. 2007. PMID: 17521775 Free PMC article. Review.
-
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii70-6. doi: 10.1136/ard.2007.078519. Ann Rheum Dis. 2007. PMID: 17934101 Free PMC article. Review.
-
Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity.Oncotarget. 2017 Sep 7;8(47):81873-81879. doi: 10.18632/oncotarget.20704. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical